MPMenelaos Pipis

Menelaos Pipis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Menelaos Pipis has a total of 163 co-authors. Here are the top co-authors by number of shared publications:

  • Mary M. Reilly

    Department of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK

    10 shared publications
  • Mariola Skorupinska

    Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology , London WC1N 3BG , UK

    5 shared publications
  • Roy Poh

    Neurogenetics Laboratory, National Hospital for Neurology and Neurosurgery , London WC1N 3BG , UK

    5 shared publications
  • Alexander M Rossor

    Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology , London WC1N 3BG , UK

    4 shared publications
  • Christopher J. Record

    Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK

    4 shared publications
  • Julian Blake

    Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology , London WC1N 3BG , UK

    4 shared publications

Latest Publications

  • Open Access

    Expanding the Phenotypic Spectrum of PMPCB ‐Related Disease: Long‐Term Survival with Childhood‐Onset Ataxia

    by Ioannis Livanos, Christina Votsi, Marios Tomazou, Hermione Ugolini, Henry Houlden, Menelaos Pipis, Eleni Zamba Papanicolaou, Kyproula Christodoulou

  • Open Access

    Making Genomic Data Actionable in Electronic Health Records: Practical Viewpoint on Standards, Governance, and Implementation

    by Styliana Menelaou, Eirini C Schiza, Marios Tomazou, Andreas Neocleous, Anastasis Oulas, Menelaos Pipis, Andreas Menikou, Athina Theodosiou, Maria Papaioannou, Carolina Sismani, et al.

    Electronic health records (EHRs) are central to patient-centered care. However, many current EHR systems do not represent, exchange, or reuse genomic findings in structured, interoperable, and clinically actionable forms. Instead, genomic results are often retained in static reports. This limits their use in routine clinical care and clinical decision support. It also restricts their future reinterpretation as scientific knowledge evolves, as well as their reuse for research within appropriate governance frameworks. To support precision and personalized medicine, we advocate that clinically relevant genomic findings should be represented within EHRs as structured, phenotype-linked, interoperable, and versioned data. Raw and intermediate genomic files, however, should remain in appropriately governed laboratory or genomics repositories. This viewpoint is intended for health policymakers, health informatics leaders, EHR developers, research and clinical genomics laboratories, and clinicians involved in implementing genomics into routine care. It is informed by selected published literature and relevant technical standards. It is also informed by operational experience at the Cyprus Institute of Neurology and Genetics and multidisciplinary discussions from the Gen2EHR Implementation Guidelines Workshop conducted within the Extended EHR@EU Data Space and European Health Data Space for Secondary Use @CY initiatives. We examine technical, organizational, clinical, ethical, legal, and governance challenges, including inconsistent reporting formats and unclear clinical responsibility. We propose a staged, workshop-informed implementation pathway for evaluation within the European Health Data Space. The pathway combines Health Level 7 Fast Health Interoperability Resources Genomics Reporting with complementary standards and terminologies. It also includes transitional dual PDF and structured Fast Health Interoperability Resources reporting, governance for access, version control, reinterpretation, and clinical responsibility, as well as multidisciplinary pilot validation in real diagnostic workflows. The clinical effectiveness and transferability of the proposed pathway across European health systems remain to be established.

  • Open Access

    Biallelic variants in COX18 cause a mitochondrial disorder primarily manifesting as peripheral neuropathy

    by Camila Armirola-Ricaurte, Laura Morant, Isabelle Adant, Sherifa A Hamed, Menelaos Pipis, Stephanie Efthymiou, Silvia Amor-Barris, Derek Atkinson, Liedewei Van de Vondel, Aleksandra Tomic, et al.

    Defects in mitochondrial dynamics are a common cause of Charcot–Marie–Tooth disease (CMT), whereas primary deficiencies in the mitochondrial respiratory chain (MRC) are rare and atypical for this aetiology. This study aims to report COX18 as a novel CMT-causing gene. This gene encodes an assembly factor of mitochondrial Complex IV that translocates the C-terminal tail of MTCO2 across the mitochondrial inner membrane. Exome sequencing was performed in four affected individuals from three families. The patients and available family members underwent thorough neurological and electrophysiological assessment. The impact of one of the identified variants on splicing, protein levels and mitochondrial bioenergetics was investigated in patient-derived lymphoblasts. The functionality of the mutant protein was assessed using a proteinase K protection assay and immunoblotting. Neuronal relevance of COX18 was assessed in a Drosophila melanogaster knockdown model. Exome sequencing coupled with homozygosity mapping revealed a homozygous splice variant c.435–6A>G in COX18 in two siblings with early-onset progressive axonal sensorimotor peripheral neuropathy. By querying external databases, we identified two additional families with rare deleterious biallelic variants in COX18. All eight affected individuals presented with axonal CMT, and some patients also exhibited CNS symptoms, such as dystonia and spasticity. Functional characterization of the c.435-6A>G variant demonstrated that it leads to the expression of an alternative transcript that lacks exon 2, resulting in a stable but defective COX18 isoform. The mutant protein impairs Complex IV assembly and activity, leading to a reduction in mitochondrial membrane potential. Downregulation of the COX18 homologue in D. melanogaster resulted in signs of neurodegeneration, including locomotor deficit and progressive axonal degeneration of sensory neurons. Our study presents genetic and functional evidence that supports COX18 as a newly identified gene candidate for autosomal recessive axonal CMT with or without CNS involvement. These findings emphasize the significance of peripheral neuropathy within the spectrum of primary mitochondrial disorders, in addition to the role of mitochondrial Complex IV in the development of CMT. Our research has important implications for the diagnostic work-up of CMT patients.

  • Top Cited Papers
    Open Access

    Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease

    by Christopher J Record, Menelaos Pipis, Mariola Skorupinska, Julian Blake, Roy Poh, James M Polke, Kelly Eggleton, Tina Nanji, Stephan Zuchner, Andrea Cortese, et al.

    Charcot-Marie-Tooth disease (CMT) is one of the most common and genetically heterogeneous inherited neurological diseases, with more than 130 disease-causing genes. Whole genome sequencing (WGS) has improved diagnosis across genetic diseases, but the diagnostic impact in CMT is yet to be fully reported. We present the diagnostic results from a single specialist inherited neuropathy centre, including the impact of WGS diagnostic testing. Patients were assessed at our specialist inherited neuropathy centre from 2009 to 2023. Genetic testing was performed using single gene testing, next-generation sequencing targeted panels, research whole exome sequencing and WGS and, latterly, WGS through the UK National Health Service. Variants were assessed using the American College of Medical Genetics and Genomics and Association for Clinical Genomic Science criteria. Excluding patients with hereditary ATTR amyloidosis, 1515 patients with a clinical diagnosis of CMT and related disorders were recruited. In summary, 621 patients had CMT1 (41.0%), 294 CMT2 (19.4%), 205 intermediate CMT (CMTi, 13.5%), 139 hereditary motor neuropathy (HMN, 9.2%), 93 hereditary sensory neuropathy (HSN, 6.1%), 38 sensory ataxic neuropathy (2.5%), 72 hereditary neuropathy with liability to pressure palsies (HNPP, 4.8%) and 53 ‘complex’ neuropathy (3.5%). Overall, a genetic diagnosis was reached in 76.9% (1165/1515). A diagnosis was most likely in CMT1 (96.8%, 601/621), followed by CMTi (81.0%, 166/205) and then HSN (69.9%, 65/93). Diagnostic rates remained less than 50% in CMT2, HMN and complex neuropathies. The most common genetic diagnosis was PMP22 duplication (CMT1A; 505/1165, 43.3%), then GJB1 (CMTX1; 151/1165, 13.0%), PMP22 deletion (HNPP; 72/1165, 6.2%) and MFN2 (CMT2A; 46/1165, 3.9%). We recruited 233 cases to the UK 100 000 Genomes Project (100KGP), of which 74 (31.8%) achieved a diagnosis; 28 had been otherwise diagnosed since recruitment, leaving a true diagnostic rate of WGS through the 100KGP of 19.7% (46/233). However, almost half of the solved cases (35/74) received a negative report from the study, and the diagnosis was made through our research access to the WGS data. The overall diagnostic uplift of WGS for the entire cohort was 3.5%. Our diagnostic rate is the highest reported from a single centre and has benefitted from the use of WGS, particularly access to the raw data. However, almost one-quarter of all cases remain unsolved, and a new reference genome and novel technologies will be important to narrow the ‘diagnostic gap’.


  • Nerve biopsy in T-cell lymphoma with neurolymphomatosis: where and when

    by Menelaos Pipis, Zane Jaunmuktane, Teresa Marafioti, Sebastian Brandner, Elaine C Smith, Shirley D'SA, Michael P Lunn, Kate Cwynarski, Doreen Fialho, Sachit Shah, et al.

    Peripheral T-cell lymphomas are rare heterogeneous haematological malignancies that may also involve peripheral nerves in a very small subset of cases. We report a patient with a diagnostically challenging cutaneous T-cell lymphoma and multifocal mononeuropathies in whom a targeted nerve biopsy identified lymphomatous infiltration of nerves and expedited combination treatment with chemotherapy and an autologous stem cell transplant. She showed an excellent response with a complete metabolic response on positron emission tomography imaging and significant clinical improvement, maintained 5 years post-treatment.

  • Quantitative MRI outcome measures in CMT1A using automated lower limb muscle segmentation

    by Luke F O'DOnnell, Menelaos Pipis, John S Thornton, Baris Kanber, Stephen Wastling, Amy McDowell, Nick Zafeiropoulos, Matilde Laura, Mariola Skorupinska, Christopher J Record, et al.

    Background Lower limb muscle magnetic resonance imaging (MRI) obtained fat fraction (FF) can detect disease progression in patients with Charcot-Marie-Tooth disease 1A (CMT1A). However, analysis is time-consuming and requires manual segmentation of lower limb muscles. We aimed to assess the responsiveness, efficiency and accuracy of acquiring FF MRI using an artificial intelligence-enabled automated segmentation technique. Methods We recruited 20 CMT1A patients and 7 controls for assessment at baseline and 12 months. The three-point-Dixon fat water separation technique was used to determine thigh-level and calf-level muscle FF at a single slice using regions of interest defined using Musclesense, a trained artificial neural network for lower limb muscle image segmentation. A quality control (QC) check and correction of the automated segmentations was undertaken by a trained observer. Results The QC check took on average 30 seconds per slice to complete. Using QC checked segmentations, the mean calf-level FF increased significantly in CMT1A patients from baseline over an average follow-up of 12.5 months (1.15%±1.77%, paired t-test p=0.016). Standardised response mean (SRM) in patients was 0.65. Without QC checks, the mean FF change between baseline and follow-up, at 1.15%±1.68% (paired t-test p=0.01), was almost identical to that seen in the corrected data, with a similar overall SRM at 0.69. Conclusions Using automated image segmentation for the first time in a longitudinal study in CMT, we have demonstrated that calf FF has similar responsiveness to previously published data, is efficient with minimal time needed for QC checks and is accurate with minimal corrections needed.


  • Open Access

    Post-transcriptional microRNA repression of PMP22 dose in severe Charcot-Marie-Tooth disease type 1

    by Menelaos Pipis, Seongsik Won, Roy Poh, Stephanie Efthymiou, James M Polke, Mariola Skorupinska, Julian Blake, Alexander M Rossor, John J Moran, Pinki Munot, et al.

    Copy number variation (CNV) may lead to pathological traits, and Charcot-Marie-Tooth disease type 1A (CMT1A), the commonest inherited peripheral neuropathy, is due to a genomic duplication encompassing the dosage-sensitive PMP22 gene. MicroRNAs act as repressors on post-transcriptional regulation of gene expression and in rodent models of CMT1A, overexpression of one such microRNA (miR-29a) has been shown to reduce the PMP22 transcript and protein level. Here we present genomic and functional evidence, for the first time in a human CNV-associated phenotype, of the 3′ untranslated region (3′-UTR)-mediated role of microRNA repression on gene expression. The proband of the family presented with an early-onset, severe sensorimotor demyelinating neuropathy and harboured a novel de novo deletion in the PMP22 3′-UTR. The deletion is predicted to include the miR-29a seed binding site and transcript analysis of dermal myelinated nerve fibres using a novel platform, revealed a marked increase in PMP22 transcript levels. Functional evidence from Schwann cell lines harbouring the wild-type and mutant 3′-UTR showed significantly increased reporter assay activity in the latter, which was not ameliorated by overexpression of a miR-29a mimic. This shows the importance of miR-29a in regulating PMP22 expression and opens an avenue for therapeutic drug development.


  • Unusual upper limb features in SORD neuropathy

    by Christopher J Record, Menelaos Pipis, Julian Blake, Riccardo Curro, Michael P Lunn, Alexander M Rossor, Matilde Laura, Andrea Cortese, Mary M Reilly


  • Open Access

    Charcot-Marie-Tooth disease type 2CC due toNEFHvariants causes a progressive, non-length-dependent, motor-predominant phenotype

    by Menelaos Pipis, Andrea Cortese, James M Polke, Roy Poh, Jana Vandrovcova, Matilde Laura, Mariola Skorupinska, Arnaud Jacquier, Raul Juntas-Morales, Philippe Latour, et al.

    Objective: Neurofilaments are the major scaffolding proteins for the neuronal cytoskeleton, and variants inNEFHhave recently been described to cause axonal Charcot-Marie-Tooth disease type 2CC (CMT2CC).Methods: In this large observational study, we present phenotype–genotype correlations on 30 affected and 3 asymptomatic mutation carriers from eight families.Results: The majority of patients presented in adulthood with motor-predominant and lower limb-predominant symptoms and the average age of onset was 31.0±15.1 years. A prominent feature was the development of proximal weakness early in the course of the disease. The disease progressed rapidly, unlike other Charcot-Marie-Tooth disease (CMT) subtypes, and half of the patients (53%) needed to use a wheelchair on average 24.1 years after symptom onset. Furthermore, 40% of patients had evidence of early ankle plantarflexion weakness, a feature which is observed in only a handful of CMT subtypes. Neurophysiological studies and MRI of the lower limbs confirmed the presence of a non-length-dependent neuropathy in the majority of patients.All families harboured heterozygous frameshift variants in the last exon ofNEFH, resulting in a reading frameshift to an alternate open reading frame and the translation of approximately 42 additional amino acids from the 3' untranslated region (3′-UTR).Conclusions: This phenotype–genotype study highlights the unusual phenotype of CMT2CC, which is more akin to spinal muscular atrophy rather than classic CMT. Furthermore, the study will enable more informative discussions on the natural history of the disease and will aid inNEFHvariant interpretation in the context of the disease’s unique molecular genetics.